Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
The three-model screen
all 1,000 screened works →All three models called this out of scope.
Meta-analysis of randomized trials of pemetrexed in non-small-cell lung cancer; a synthesis method used to answer a clinical question, the paradigm OUT case in the rubric.
The meta-analysis answers a clinical treatment question rather than studying how meta-analyses are done.
Clinical meta-analysis of pemetrexed for lung cancer; method used to answer a treatment question.
Abstract
PURPOSE: Platinum-based regimens represent the standard first-line treatment for non-small-cell lung cancer (nsclc). However, newer data have established a role for pemetrexed in the treatment of this disease. Such data suggest that histology represents a determining factor in the selection of treatment. METHODS: We undertook a systematic review of the literature for randomized controlled trials that compared the efficacy of pemetrexed with that of other treatments in advanced nsclc. Data and study quality were assessed according to published guidelines. RESULTS: We identified five trials that compared pemetrexed with other treatments or with placebo. Overall survival for patients treated with pemetrexed was superior to that with other treatments: hazard ratio (hr): 0.89; 95% confidence interval (ci): 0.80 to 0.99. The survival benefit was limited to patients with non-squamous histology: hr: 0.82; 95% ci: 0.73 to 0.91. Pemetrexed was inferior to other chemotherapy options in patients with squamous histology: hr: 1.19; 95% ci: 0.99 to 1.43. CONCLUSIONS: Compared with other chemotherapy agents, pemetrexed is more effective for the treatment of nsclc in patients with non-squamous histology.
Stored with the screening record, where it is evidence for the labels above.
The record
- Venue
- Current Oncology
- Topic
- Lung Cancer Treatments and Mutations
- Field
- Medicine
- Canadian institutions
- McMaster UniversityJuravinski Cancer CentreCredit Valley Hospital
- Funders
- —
- Keywords
- PemetrexedMedicineInternal medicineLung cancerHazard ratioOncologyChemotherapyHistologyRandomized controlled trialPlaceboConfidence intervalPathologyCisplatin
- Has abstract in OpenAlex
- yes